🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Rapamune 1 mg coated tablets, MYCOPHENOLATE MOFETIL

    The George Institute

    End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA

    approved small molecule active

    1 trial

  2. Rapid Acting insulin with pre-treatment of rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

  3. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

  4. Recaticimab

    The First People's Hospital of Lianyungang

    STEMI - ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  5. Recaticimab and Statin

    The First People's Hospital of Lianyungang

    Intracranial Atherosclerosis

    approved small molecule active

    1 trial

  6. Recigarum 1,5 mg comprimidos recubiertos con película EFG

    The George Institute

    Active smokers

    approved small molecule active

    1 trial

  7. Recombinant FSH (follitropin alpha)

    United Therapeutics Europe Ltd

    Ovulation Induction

    approved small molecule completed

    1 trial

  8. Recombinant Human Adenovirus Type 5 injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  9. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule completed

    1 trial

  10. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    ST-segment Elevation Myocardial Infarction (STEMI)

    approved small molecule completed

    1 trial

  11. Recombinant staphylokinase

    The First People's Hospital of Lianyungang

    ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  12. Recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules)

    United Therapeutics Europe Ltd

    Diarrhea

    approved mab active

    1 trial

  13. Regiocit solution pour hémofiltration

    Pari Pharma GmbH

    Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay.

    approved small molecule active

    1 trial

  14. Regional Anesthesia

    BRIGHT MINDS BIOSCIENCES INC.

    Inguinal Hernia

    approved small molecule completed

    1 trial

  15. Remimazolam Besylate for Injection

    The First People's Hospital of Lianyungang

    Thoracic Surgery

    approved small molecule active

    1 trial

  16. Remodulin

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    approved small molecule completed

    1 trial

  17. Resveratrol

    The First People's Hospital of Lianyungang

    Pancreatitis, Acute

    approved small molecule active

    1 trial

  18. Reveal® XT Insertable Cardiac Monitor

    Rhythm Pharmaceuticals Netherlands B.V.

    Cryptogenic Symptomatic Transient Ischemic Attack

    approved other completed

    1 trial

  19. Revefenacin

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease

    approved small molecule completed

    1 trial

  20. Rifaldin 300 mg cápsulas, Rimactán 300 mg cápsulas duras, Cemidón 300 B6, RIFAPENTINE

    The George Institute

    Latent tuberculosis infection in patients with end-stage kidney disease.

    approved small molecule active

    1 trial

  21. Rifaximin

    The First People's Hospital of Lianyungang

    IBS - Irritable Bowel Syndrome

    approved small molecule active

    1 trial

  22. Rifaximin

    United Therapeutics Europe Ltd

    Nonalcoholic Fatty Liver Disease

    approved small molecule terminated

    1 trial

  23. Rifaximin

    United Therapeutics Europe Ltd

    Clostridium Difficile Infection

    approved small molecule completed

    1 trial

  24. Rituximab

    The First People's Hospital of Lianyungang

    Hemophagocytic Lymphohistiocytosis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources